

Expanded View Figures

Figure EV1. Peripheral T cell compartment characterization of *CD4cre Ptpn6^{fl/fl}* and *CD4cre Ptpn6^{fl/fl}/Ptpn11^{fl/fl}* mice.

- A, B T cells from spleen (A) and inguinal lymph nodes (iLN) (B) of *CD4cre Ptpn6^{fl/fl}* and control mice were analyzed. Cellularity, CD4⁺ and CD8⁺ T cell numbers (gated as TCRβ⁺ CD4⁺ or CD8⁺, respectively), percentages of CD44 high T cells are shown; regulatory T cell (Treg) numbers and frequency (gated as TCRβ⁺ CD4⁺ Foxp3⁺) are illustrated for the spleen.
- C Cellularity from thymus and number of CD4 and CD8 double-negative, double-positive, CD4 or CD8 single-positive thymocytes (gated on lineage⁻; single-positives, an additional gate on TCRβ⁺ was performed) of *CD4cre Ptpn6^{fl/fl}/Ptpn11^{fl/fl}W^{bm}* and control mice are depicted.
- D Treg number and frequency (gated as TCRβ⁺ CD4⁺ Foxp3⁺) are illustrated for the spleen of *CD4cre Ptpn6^{fl/fl}/Ptpn11^{fl/fl}W^{bm}* and control mice.
- E Cellularity, CD4⁺ and CD8⁺ T cell numbers, as well as percentages of CD44 high T cells from the iLN of *CD4cre Ptpn6^{fl/fl}/Ptpn11^{fl/fl}W^{bm}* and control mice are shown.
- F Survival curves of *CD4cre Ptpn6^{fl/fl}/Ptpn11^{fl/fl}B^{gn}* and control mice challenged with MC38.
- G–I Ten to twelve days following MC38 tumor inoculation, isotype-treated *CD4cre Ptpn6/11^{wt/wt}* and *CD4cre Ptpn6^{fl/fl}/Ptpn11^{fl/fl}W^{bm}* mice were sacrificed. Graph depicts the frequencies of PD-1⁺ CD8⁺ T cells (gated as CD45⁺ TCRβ⁺ CD8⁺) in the tumor (G). Frequencies of CD4⁺ T cells (gated as CD45⁺ TCRβ⁺ CD4⁺) expressing IFN-γ and TNFα upon re-stimulation (H) and percentages of CD4⁺ T cells in the tumor are shown (I).

Data information: Results illustrate mean ± SEM of *n* = 7–8 mice/group (A, B), of *n* = 10–12 mice/group (C–E), or of *n* = 9–14 mice/group (G–I). Student's *t*-test (unpaired, two-tailed) was used to compare differences between experimental groups (A–E, G–I). Results depict *n* = 11 mice/group; statistical significance was calculated by log-rank (Mantel-Cox) test (F). **P* ≤ 0.05, ***P* ≤ 0.01, ****P* ≤ 0.001, *****P* ≤ 0.0001.

Source data are available online for this figure.




Figure EV1.




Figure EV2. Peripheral T cell compartment characterization of *GzmBcre Ptpn6/11^{fl/fl}* mice.

A–D Spleen and iLN of *GzmBcre Ptpn6/11^{fl/fl}* mice and control mice were analyzed. Cellularity, CD4⁺ and CD8⁺ T cell numbers are depicted for spleen (A) and iLN (B). Percentages of CD44 high of CD4⁺ and CD8⁺ T cells are shown for spleen (C) and iLN (D). Results depict $n = 6–7$ mice/group (A, B) and $n = 4$ mice/group for percentages of CD44 high cells (C, D). Student's t-test (unpaired, two-tailed) was used to compare differences between experimental groups.

E Tumor growth in individual mice challenged with MC38 is shown for the indicated genotypes; number of mice eradicating the tumor is shown within the graphs.

Source data are available online for this figure.




Figure EV3. Characterization of CTLs from *Ptpn6/11^{fl/fl}* and *GzmBcre Ptpn6/11^{fl/fl}* mice.

CD8⁺ cytotoxic lymphocytes were generated from splenocytes of the indicated mice by anti-CD3, anti-CD28, and IL-12 stimulation and maintained in IL-2.

A, B CD8⁺ T cells were analyzed by flow cytometry for surface expression of GITR and CD71 after 2 days (A) and for surface expression of GITR, CD71, CD69, and CD44 after 5 days (B); a quantification of these parameters is shown in the graphs (A and B).

C Graphs depict the percentages of cells in G1, S, and G2 phase as measured by flow cytometry-based cell cycle analysis of *Ptpn6/11^{fl/fl}* and *GzmBcre Ptpn6/11^{fl/fl}* CTLs (gated on CD8⁺ T cells) at the indicated days.

Data information: Results depict mean \pm SD of $n = 3$ biological replicates and Student's t -test (unpaired, two-tailed) was used to compare differences between experimental groups (A–C). * $P \leq 0.05$.

Source data are available online for this figure.